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Poly‑arginine peptides reduce infarct
volume in a permanent middle cerebral artery
rat stroke model
Diego Milani2,3,4, Vince W. Clark1,2,3, Jane L. Cross1,2,3, Ryan S. Anderton3,4, Neville W. Knuckey1,2,3
and Bruno P. Meloni1,2,3*

Abstract
Background: We recently reported that poly-arginine peptides have neuroprotective properties both in vitro and
in vivo. In cultured cortical neurons exposed to glutamic acid excitotoxicity, we demonstrated that neuroprotective
potency increases with polymer length plateauing at R15 to R18 (R = arginine resides). In an in vivo study in rats,
we also demonstrated that R9D (R9 peptide synthesised with D-isoform amino acids) administered intravenously at
a dose of 1000 nmol/kg 30 min after permanent middle cerebral artery occlusion (MCAO) reduces infarct volume.
Based on these positive in vitro and in vivo findings, we decided to examine the neuroprotective efficacy of the
L-isoform poly-arginine peptides, R12, R15 and R18 when administered at a dose of 1000 nmol/kg 30 min after permanent MCAO in the rat.
Results: At 24 h post-MCAO, there was reduced total infarct volume for R12 (12.8 % reduction) and R18 (20.5 %
reduction), but this reduction only reached statistical significance for R18. Brain slice analysis revealed significantly
reduced injury in coronal slices 4 and 5 for R18, and slice 5 for R12. The R15 peptide had no effect on infarct volume.
Peptide treatment did not reveal any statistical significant improvement in functional outcomes.
Conclusion: While these findings confirm the in vivo neuroprotective properties of poly-arginine peptides, additional dose studies are required particularly in less severe transient MCAO models so as to further assess the potential
of these agents as a stroke therapy.
Keywords: Poly-arginine peptides, Middle cerebral artery occlusion, Stroke, Neuroprotection
Background
Minimising brain injury following stroke is a critical
clinical goal both to improve patient quality of life and to
lessen the social and economic impacts of this devastating
disorder. Currently, the most effective stroke therapy is to
restore cerebral blood flow to a blocked artery using tPA
and thrombectomy [1–3]. However, the current therapeutic window for coupled tPA ± thrombectomy therapy
is so narrow (4.5 h) that the majority of stroke patients
are unable to receive the treatment. Moreover, for those
that do, up to 7 % develop intracranial haemorrhage as a
*Correspondence: bruno.meloni@wanri.uwa.edu.au
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complication. In addition, tPA ± thrombectomy is only
available to patients having ready access to a hospital that
has the facilities required for performing the procedures.
Other treatments are only suitable for a small proportion
of patients (e.g. hemicraniectomy to reduce intracranial
pressure due to cerebral oedema) or provide only modest
benefit (e.g. aspirin to reduce risk of clot propagation) [4].
As a consequence, while recent improvements in stroke
therapy have been made, these have been limited and it
is clear that there is urgent need for new, more widely
applicable neuroprotective therapies that can be applied
to stroke patients early by ambulance paramedics, in hospital emergency departments, and in remote locations
away from tertiary hospitals. Additionally, any treatment that might improve the safety, therapeutic window
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and neuroprotective outcomes for tPA ± thrombectomy
would be of great clinical significance.
Against the backdrop of the limited nature of current
therapies, we have recently demonstrated that poly-arginine (and arginine-rich) peptides have potent neuroprotective properties in in vitro injury models that mimic
the effects of stroke [5–7]. We have also established that
poly-arginine peptides, as well as other arginine-rich
peptides, including TAT and penetratin belonging to a
class of peptide with cell penetrating properties also possess intrinsic neuroprotective properties [5–7]. Moreover, our in vitro data show that neuroprotective potency
is enhanced with increasing arginine content (e.g. polymer length) [6]. As evidence of their clinical applicability, we have demonstrated that the poly-arginine R9D
significantly reduces infarct volume in vivo following
permanent middle cerebral artery occlusion (MCAO) in
the rat [6]. A recent report [8] has also demonstrated that
poly-arginine 7 (R7) containing peptides are neuroprotective in an in vivo retinal ganglion NMDA excitotoxicity model.
The neuroprotective properties of poly-arginine peptides in vitro and in vivo suggest that they may have
potential as a neuroprotective therapy for stroke patients.
To further investigate the efficacy of poly-arginine peptides in vivo and given the positive results obtained with
the R9D peptide, in this study we assess the neuroprotective efficacy of the longer L-isoform poly-arginine
peptides R12, R15 and R18 when administered 30 min
after permanent MCAO. In addition, unlike in our earlier R9D trial, this study assesses functional outcomes
using three behavioural tests as well as infarct volume to
gain an understanding of the functional consequences of
neuroprotection.

Results
Physiological and infarct volume measurements

Physiological measurements before or during surgery
confirmed the absence of any significant differences
between animal treatment groups (Table 1). Data on
the mean total infarct volumes and representative TTC

stained coronal brain slices for each treatment group are
presented in Fig. 1. These results show that the R18 peptide significantly reduced infarct volume (20.5 % reduction; P = 0.014). The R12 peptide also reduced infarct
volume (12.8 % reduction), but not to a statistical significant extent (P = 0.105). By contrast, the R15 peptide
had no effect on infarct volume. Rostral to caudal topographic analysis of infarcts in brain slices revealed that
the R18 peptide significantly reduced brain injury in coronal slices 4 (P = 0.008) and 5 (P = 0.01) (Fig. 2). In addition, the R12 peptide significantly reduced brain injury in
coronal slice 5 (P = 0.027).
There were three post-treatment animal deaths that
occurred the day following surgery, one in the vehicle and
two in the R12-treated animals. While the animal deaths
could be directly related to stroke severity and/or treatment, the exact cause of the deaths could not be precisely
determined on autopsy.
Functional outcome assessment

Neurological scores using the modified Bederson’ scale for
each treatment group are presented in Fig. 3. While neurological scores did not differ statistically between groups,
the vehicle control group score was higher (1.9) than any of
the scores for the peptide treatment groups (<1.4), indicative of a possible positive treatment effect. Results for the
rota-rod assessment for each treatment group are presented in Fig. 4. Results were highly variable within groups
and no significant differences were detected.
For the adhesive tape removal test pre- and postMCAO measurements for time to detect tape, the number of attempts to remove tape and time taken to remove
tape for each treatment group are presented in Fig. 5.
As expected, the left paw was more adversely affected
than the right paw, however there were no statistically
significant differences between vehicle-treated versus
peptide-treated groups. However, for the R12 peptide all
parameters measured for the left paw, and two out of the
three measurements obtained for the right paw showed a
positive improvement, albeit not to a statistically significant extent.

Table 1 Physiological parameters for experimental animals used in study

PaO2 (mmHg)
PaCO2 (mmHg)
pH
Glucose (mmol/L)
Blood pressure (mmHg)
Body temperature (°C)

Saline (N = 12)

R12 (N = 9)

R15 (N = 8)

R18 (N = 8)

115.10 ± 33.51

124.30 ± 18.40

112.80 ± 16.96

120.60 ± 20.34

7.44 ± 0.09

7.33 ± 0.08

7.31 ± 0.09

7.42 ± 0.08

42.92 ± 5.82

7.74 ± 1.27

89.00 ± 8.44

37.48 ± 0.18

46.00 ± 4.21

7.42 ± 1.06

78.44 ± 6.98

37.58 ± 0.13

39.38 ± 5.20

7.03 ± 1.11

88.00 ± 9.97

37.46 ± 0.21

44.25 ± 7.74

7.13 ± 1.08

79.63 ± 12.65
37.51 ± 0.06

PaO2, PaCO2, pH, blood pressure and glucose measured before MCAO. Body temperature data represent average over 2 h post-surgery monitoring period. Data are
mean ± SD
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Fig. 3 Neurological grading scores 24 h after permanent MCAO
(0 = no deficit, 4 = major deficit) for saline (vehicle) and peptide
(R12, R15, R18; 1000 nmol/kg) treatment groups. Assessment was
performed immediately before euthanasia. Lines on graph indicate
range and median for neurological scores
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Fig. 1 Infarct volume measurements and coronal brain slices 24 h
after permanent MCAO. Treatments were administered intravenously
(saline vehicle or peptide 1000 nmol/kg; in 600 µl volume over 6 min)
30 min after MCAO. a Values are mean ± SD. *P < 0.05 when compared to the vehicle control group. †Denotes animals that died the
following day after surgery, before the 24 h post-MCAO end-point,
but whose infarct volume was measured nonetheless. b Representative TTC coronal brain slices from vehicle and peptide treated animals

250
200
150
100
50
0

Vehicle

R12

R15

R18

Fig. 4 Rota-rod performance 24 h after permanent MCAO for saline
(vehicle) and peptide (R12, R15, R18; 1000 nmol/kg) treatment
groups. Results for this test were highly variable within groups and
no significant differences were detected. Average time healthy presurgery animals remained on rota-rod was 78 s (data not shown).
Values are mean ± SD

Weight loss measurement

At experiment end, all treatment groups recorded a loss
in weight, with the greatest weight loss occurring in the
R15 peptide treatment group (P = 0.004; Fig. 6).
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Fig. 2 Infarct volume analysis in coronal brain slices (1–6 from rostral
to caudal). The R18 peptide significantly reduced injury in brain slices
4 and 5, and the R12 peptide significantly reduced brain injury in slice
5. Values are mean ± SD; *P < 0.05 when compared to the vehicle
control group

Discussion
In a previous study, we demonstrated that the poly-arginine peptide R9D could reduce infarct volume by 20 %
when administered intravenously 30 min post-MCAO
[6], however no functional assessment was performed.
The present study extends this previous study to include
the poly-arginine peptides R12, R15 and R18 and explores
their capacity to reduce infarct volume and improve functional outcomes when administered intravenously 30 min
post-MCAO. Whereas R15 had no effect on infarct volume, R18 significantly reduced infarct volume (20.5 %
reduction) and there was a trend towards reduced infarct
volume with R12 (12.8 % reduction). Importantly, all peptide treatments displayed a trend towards improvement
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Fig. 5 Functional assessment measurements using adhesive tape removal test before and 24 h after MCAO for saline (vehicle) and peptide (R12,
R15, R18; 1000 nmol/kg) treatment groups. Post-MCAO assessment was performed immediately before euthanasia. No treatment significantly
improved adhesive tape detection or removal times for the left or right paw. Values are mean ± SD; N = 11 for vehicle, N = 7 for R12, N = 8 for R15
and N = 8 for R18. Maximum time allowed for adhesive tape removal was 120 s

in one or more of the neurological functional tests.
Whilst the level of infarct volume reduction was modest (12.8–20.5 %), this most likely reflects the severity of
the stroke model used in this particular study where up
to 90 % of the affected brain hemisphere is infarcted by
the stroke. It is also likely that the modest reductions in
infarct volume, stroke severity and 24-h endpoint coupled with the small animal numbers used explain why the
trend towards improvements in functional outcomes was

not statistically significant. Despite the modest effects of
the poly-arginine peptides following permanent MCAO,
it is still possible that these peptides have potential clinical application, especially in less severe forms of stroke,
stroke associated with cerebral reperfusion treatments
(tPA ± thrombectomy) and haemorrhagic stroke.
With respect to neuroprotective efficacy, further
research is required to determine the optimal dose of
the peptides to reduce infarct volume. It was particularly
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Fig. 6 Weight loss at 24 h after permanent MCAO for saline (vehicle)
and peptide (R12, R15, R18; 1000 nmol/kg) treatment groups. Values
are mean ± SD; *P < 0.05 when compared to the vehicle control
group

surprising that the R15 peptide did not have any affect
on infarct volume reduction, despite showing comparable neuroprotective efficacy to R18 when assessed in an
in vitro neuronal glutamate excitotoxicity model [6]. The
reason why no observable neuroprotection was obtained
for R15 is at present unknown, but it is possible that a
higher or lower dose may be more effective than the dose
used in the current study. Studies are currently underway
in our laboratory to more definitively address questions
surrounding effective dosage for a range of poly-arginine
peptides in the in vivo stroke model.
The present study did not investigate the mechanism
of action of peptides, but in previous studies we have
shown that poly-arginine peptides have the capacity to
reduce excitotoxic glutamic acid-induced calcium influx
in cultured cortical neurons [6, 7]. Based on this finding,
as well as the findings of other studies, we have hypothesised that these peptides have the capacity to inhibit calcium influx by causing the internalisation of cell surface
structures such as ion channels and thereby reduce the
toxic neuronal calcium entry that occurs after excitotoxicity and cerebral ischemia. We have speculated that due
to the cell penetrating properties of arginine-rich peptides, including putative “neuroprotective peptides” fused
to the arginine-rich carrier peptide TAT, ion channel
receptor internalisation occurs during neuronal endocytic uptake of the peptides [6, 7]. Evidence that supports our hypothesis includes studies demonstrating that
arginine-rich peptides: (1) interfere with the function
of NMDA [9–14] and vanilloid receptors [15], voltage
gated calcium channels [16–18] and the sodium calcium
exchanger [13]; (2) cause internalisation or reduced surface expression of neuronal ion channels [11, 13, 18]; and
(3) can induce the endocytic internalisation of epidermal
growth factor receptor and tumour necrosis factor receptors in HeLa cells [19].

In support of the poly-arginine neuroprotective findings in the present study, a recent report [8] has confirmed the neuroprotective properties of poly-arginine
7 (R7) containing peptides and other arginine-rich peptides (TAT and TATNR2B9c) in an in vivo retinal ganglion NMDA excitotoxicity model. Moreover, the study
also provides evidence for an additional neuroprotective
mechanism associated with maintenance of mitochondrial function and integrity.
Studies in our laboratory to confirm peptide-induced
internalisation of cell surface receptors and other neuroprotective mechanisms are in progress. While we have
demonstrated that arginine-rich peptides have the capacity to reduce excitotoxic calcium influx, it will be important to obtain a more comprehensive understanding of
peptide neuroprotective mechanism of action. Nevertheless our findings indicate poly-arginine peptides have
both in vitro and in vivo neuroprotective properties and
warrant further evaluation in different stroke models and
other acute brain injury disorders.

Conclusion
The findings of this study further validates the neuroprotective properties of poly-arginine peptides [5–9], highlights their status a new class of neuroprotective agent
and provides justification for their evaluation in different
stroke models and other acute brain injury disorders. The
findings also further question the mechanism of action of
the many reported “neuroprotective peptides” fused to
arginine-rich carrier peptides, which are thought to act
through interaction with specific intracellular proteins,
but which our data suggest may act through a common
mechanism of action relating to peptide arginine content
and positive charge.
Methods
Peptides

The R12 (H-RRRRRRRRRRRR-OH), R15 (H-RRRRRR
RRRRRRRRR-OH) and R18 H-RRRRRRRRRRRRRR
RRRR-OH) peptides used in the study were synthesised
by China Peptides (Shanghai, China). The peptides were
HPLC purified to >94 % purity. All peptides were prepared in 0.9 % sodium chloride for injection (Pfizer,
Perth, Australia) aliquoted into 650 µl volumes in 3 ml
syringes and stored at −20 °C until use.
Rat permanent middle cerebral artery occlusion procedure

This study was approved by the Animal Ethics Committee of the University of Western Australia and follows
guidelines outlined by the Australian Code for the Care
and use of Animals for Scientific Purposes. The experimental procedure for performing the permanent middle cerebral artery occlusion (MCAO) stroke model
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has been described previously [20, 21]. Briefly, male
Sprague–Dawley rats weighing 270–320 g were kept
under controlled housing conditions with a 12 h light–
dark cycle and with free access to food and water. Experimental animals were fasted overnight and subjected
to filament permanent MCAO. In order to monitor
blood pressure and withdraw blood samples, a cannula
was inserted in the tail artery. Between 50 and 200 µL
of blood was used for glucose (glucometer; MediSense
Products, Abbott Laboratories, Bedford, MA, USA) and
other measurements (PaO2, PaCO2, pH; ABL5, Radiometer, Copenhagen, Denmark). The MCAO procedure
was considered successful based on a >25 % decrease
from baseline in cerebral blood flow (CBF) after insertion of filament, as measured by laser Doppler flowmetry. During surgery temperature was closely monitored
using a rectal probe (Physitemp Instruments, Clifton,
USA) and maintained at 37.5 ± 0.5 °C, with fan heating
or cooling.
Thirty minutes post-MCAO, rats were intravenously
treated with the peptide (1000 nmol/kg in 600 µL over
6 min) or vehicle (0.9 % sodium chloride for injection;
600 µL over 6 min). Treatments were administered via
the right internal jugular vein and infusion pump. Treatments were randomised and all procedures were performed blinded to treatment.
Twenty-fours hours post-MCAO, infarct area assessment was performed by preparing 2 mm thick cerebral
coronal brain slices, and incubating in 3 % 2,3,5 triphenyltetrazolium chloride (TTC; Sigma-Aldrich, St.
Louis, USA) at 37 °C for 20 min, followed by fixation
in 4 % formalin at room temperature overnight. Digital
images of coronal sections were acquired using a colour scanner and analysed by an operator blind to treatment status, using ImageJ software (3rd edition, NIH,
Bethesda, USA). The total infarct volume was determined by measuring the areas of infarcted tissue on
both sides of the 2 mm sections. These measured areas
were corrected for cerebral oedema by multiplying the
infarct volume for the oedema index (calculated by
dividing the total volume of the stroke-affected hemisphere by the total volume of the contralateral hemisphere) [22].
A total of 42 animals were used in the trial. Five animals were excluded from the study; two animals were
euthanased due to subarachnoid haemorrhage, one animal was excluded due to insufficient decrease in CBF, one
animal was excluded due to pyrexia, and one died during
surgical recovery for an unknown reason.
Post‑surgical monitoring

Following surgery animals were placed in a clean cage
with free access to food and water. The body temperature
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of animals was measured every 30–60 min using a rectal probe for at least 2 h post-surgery, and maintained
between 37.0 and 37.8 °C. To avoid hypothermia, rat cages
were placed on a heating mat during the post-surgical
monitoring and housed in a holding room maintained at
26–28 °C. If necessary, additional heating or cooling was
performed by applying fan heating or cold water spray.
Behavioural testing

To determine if peptide treatment was associated with
improved sensorimotor outcomes, three neurological
tests were performed 24 h post-stroke.
Neurological assessment test

The scoring system was performed using the modified
Bederson’ scale. Scores range from 0 for no deficits, 1 for
flexed forepaw, 2 for inability to resist lateral push, 3 for
circling, 4 for agitated circling and 5 for unresponsive to
stimulation/stupor [23].
Adhesive tape removal test

This is a bilateral asymmetry paw-test, which assesses
sensorimotor impairment [24]. Adhesive tape (Diversified Biotech, Dedham, USA) 10 mm × 10 mm in size
was placed on the palmar surface of the forepaw and the
time taken for the first attempt to remove tape, the number of attempts to remove tape and the total time taken
to remove tape recorded. Each forelimb was assessed
sequentially starting with the unaffected side (right
side) with animals having a maximum of 120 s to complete the task (normal rats usually take between 5 and 30
s to remove the tape). Animals were tested a total of six
times, three times on the day before surgery and three
times 24 h post-MCAO. Mean values were calculated for
each forepaw for the pre- and post-surgery trials.
Rota‑rod test

This test assesses balance and coordination by assessing a
rat’s ability to remain walking on a rotating rod when its
speed of rotation gradually increases from 4 to 40 revolutions per minute. The time at which the animal falls is
recorded. Typically rats fall 27–137 s after placement on
the rod.
Statistical analysis

Mean infarct volume measurements (total and coronal
slices) for each treatment group was compared to the
vehicle control group by analysis of variance (ANOVA)
followed by the Fisher’s post hoc analysis. Data from neurological assessment were analysed using Kruskal–Wallis
test [25]. Data from adhesive tape and rota-rod tests were
analysed using ANOVA followed by post hoc analysis
using Scheffe’s multiple comparison procedure. A value
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of P < 0.05 was considered significant for all data sets.
Data in figures are presented as mean ± standard deviation (SD).
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